Page last updated: 2024-12-05

procainamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Procainamide is a class I antiarrhythmic drug used to treat atrial fibrillation, ventricular tachycardia, and other cardiac arrhythmias. It is synthesized by reacting procaine with p-aminobenzoic acid. Procainamide works by blocking sodium channels in the heart, slowing the conduction of electrical impulses through the heart and reducing the excitability of the heart muscle. It is important because it is an effective treatment for a variety of cardiac arrhythmias. Procainamide is studied to understand its mechanisms of action and its effects on the heart, as well as to develop new and more effective antiarrhythmic drugs.'

Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4913
CHEMBL ID640
CHEBI ID8428
SCHEMBL ID15914
MeSH IDM0017605

Synonyms (168)

Synonym
BIDD:GT0579
BB 0216450
BRD-K75089421-003-04-7
BRD-K75089421-001-02-5
BRD-K75089421-003-05-4
p-amino-n-(2-diethylaminoethyl)benzamide
benzamide, p-amino-n-[2-(diethylamino)ethyl]-
p-aminobenzoic diethylaminoethylamide
nsc-27461
biocoryl
novocaine amide
wln: zr dvm2n2&2
novocainamid
novocainamide
nsc27461
benzamide, 4-amino-n-[2-(diethylamino)ethyl]-
procaine amide
pronestyl
procamide
novocamid
procapan (free base)
KBIO1_000931
DIVK1C_000931
4-amino-n-[2-(diethylamino)ethyl]benzamide
SPECTRUM_000836
benzamide, p-amino-n-(2-(diethylamino)ethyl)-
brn 2214285
procan
hsdb 3170
4-amino-n-(2-(diethylamino)ethyl)benzamide
einecs 200-078-8
procainamide [inn:ban]
2-diethylaminoethylamid kyseliny p-aminobenzoove [czech]
procainamida [inn-spanish]
nsc 27461
benzamide, 4-amino-n-(2-(diethylamino)ethyl)-
procainamidum [inn-latin]
BIO2_000663
BIO2_000183
BIO1_000880
BIO1_000391
NCGC00015859-01
lopac-p-9391
CBDIVE_003757
NCGC00015859-02
cas-614-39-1
BIO1_001369
BSPBIO_001463
PRESTWICK3_000337
IDI1_033933
BPBIO1_000411
IDI1_000931
LOPAC0_000995
SMP1_000055
BSPBIO_002229
BSPBIO_000373
PRESTWICK2_000337
SPECTRUM5_000986
AB00053530
STK367963
51-06-9
C07401
procainamide
DB01035
NCGC00024323-05
NCGC00024323-04
KBIO3_001729
KBIO2_002751
KBIO2_006452
KBIOGR_000973
KBIOGR_000183
KBIOSS_001316
KBIO2_000183
KBIO3_000365
KBIO3_000366
KBIO2_005319
KBIOSS_000183
KBIO2_001316
KBIO2_003884
MAYBRIDGE1_004389
SPBIO_002294
NINDS_000931
PRESTWICK1_000337
PRESTWICK0_000337
SPECTRUM3_000555
SPECTRUM4_000487
SPECTRUM2_001295
SPBIO_001329
NCGC00024323-03
NCGC00015859-03
NCGC00024323-06
amide, procaine
CHEBI:8428 ,
procainamidum
procainamida
rhythmin
HMS2089E13
HMS1989J05
NCGC00015859-10
sp 100 (pharmaceutical)
CHEMBL640
AKOS000271131
HMS553P13
L001052
procainamide (inn)
D08421
HMS1791J05
HMS1361J05
4-amino-n-(2-diethylaminoethyl)benzamide
NCGC00015859-07
dtxcid403512
cas-51-06-9
dtxsid7023512 ,
tox21_110246
CCG-205075
NCGC00015859-08
NCGC00015859-04
NCGC00015859-11
NCGC00015859-05
NCGC00015859-06
NCGC00015859-09
4-14-00-01154 (beilstein handbook reference)
unii-l39wtc366d
2-diethylaminoethylamid kyseliny p-aminobenzoove
l39wtc366d ,
EPITOPE ID:135397
gtpl4811
procainamide [inn]
procainamide [who-dd]
n-(2-(diethylamino)ethyl)-4-aminobenzamide
procainamide [vandf]
procainamide [hsdb]
4-amino-n-(2-diethylaminoethyl) benzamide
AB00053530-15
SCHEMBL15914
tox21_110246_1
NCGC00015859-14
AB00053530-13
4-{n-[2-(diethylamino)ethyl]carbamoyl}aniline
n-(2-diethylaminoethyl) 4-aminobenzamide
bdbm39344
cid_66068
4-azanyl-n-[2-(diethylamino)ethyl]benzamide;hydrochloride
cambridge id 5144127
4-amino-n-(diethylaminoethyl)benzamide
4-amino-n-[2-(diethylamino)ethyl]benzamide #
HMS3402J05
n1-[2-(diethylamino)ethyl]-4-aminobenzamide
AB00053530_16
F2173-1035
mfcd00066880
CS-W009100
SBI-0050968.P004
NCGC00015859-18
Q417597
BRD-K75089421-003-15-3
FS-5697
SDCCGSBI-0050968.P005
NCGC00015859-23
procanbid; sp 100; sp 100 (pharmaceutical)
C75392
NCGC00015859-16
4-amino-n-(2-diethylamino-ethyl)-benzamide
EN300-33971
HY-A0084A
c01ba02
procainamidum (inn-latin)
procainamida (inn-spanish)

Research Excerpts

Overview

Procainamide is a widely used antiarrhythmic that is fraught with therapeutic limitations such as a short half-life, production of autoimmune antibodies and a lupus-like syndrome. The disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown.

ExcerptReferenceRelevance
"Procainamide is a widely used antiarrhythmic that is fraught with therapeutic limitations such as a short half-life, production of autoimmune antibodies and a lupus-like syndrome, and complex pharmacokinetics. "( Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
Beedle, EE; Parli, CJ; Robertson, DW; Smallwood, JK; Steinberg, MI; Wilson, H, 1988
)
1.92
"Procainamide is a useful agent for management of ventricular arrhythmia, however its disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown. "( Procainamide pharmacokinetics during extracorporeal membrane oxygenation.
Rosenbaum, AN; Vollmer, NJ; Wieruszewski, PM; Wittwer, ED, 2023
)
3.8
"Procainamide is a sodium channel blocker used to diagnose BrS."( The clinical utility of procainamide-induced late potentials on the signal averaged ECG.
Alqarawi, W; Krahn, AD; Laksman, Z; Larsen, JM; Leach, E; Pearman, CM; Walia, J, 2021
)
1.65
"Procainamide is an antiarrhythmic drug of unproven efficacy in cardiac arrest. "( Procainamide and survival in ventricular fibrillation out-of-hospital cardiac arrest.
Allen, J; Eisenberg, MS; Fahrenbruch, CE; Gold, LS; Kudenchuk, PJ; Markel, DT; Rea, TD, 2010
)
3.25
"Procainamide is a competitive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decreasing Dnmt expression, and in lupus T cells decreased ERK pathway signaling causing a similar Dnmt decrease."( Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs.
Lu, Q; Richardson, BC; Wu, A, 2005
)
1.05
"Procainamide (PA) is a drug that is used to treat tachycardia in postoperative patients or for long-term maintenance of cardiac arrythmias. "( Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.
Bonini, MG; Deterding, LJ; Ehrenshaft, M; Jiang, J; Mason, RP; Siraki, AG; Tomer, KB, 2008
)
3.23
"Procainamide is an organic cation and commonly prescribed drug that is actively secreted into the urine by renal proximal tubules. "( Procainamide uptake by rabbit proximal tubules.
McKinney, TD, 1983
)
3.15
"Procainamide is a class I antiarrhythmic agent that undergoes active tubular secretion through the organic cation transport system, with approximately 50% of a dose excreted in the urine as unchanged drug. "( Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide.
Cascio, W; Griener, J; Martin, DE; Patterson, JH; Raasch, R; Shen, J, 1996
)
1.97
"Procainamide is a class IA antiarrhythmic drug indicated for the treatment of life-threatening or symptomatic ventricular arrhythmias. "( Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators.
Haber, HE; Kerin, NZ; Meengs, WL; Salerno, D; Singer, RM; Timmis, GC, 1997
)
2.05
"Procainamide hydrochloride is a Class 1A antiarrhythmic agent administered intravenously or orally for treatment of symptomatic ventricular premature depolarizations (VPD), nonsustained ventricular tachycardia, and life-threatening ventricular arrhythmias. "( Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
Abel, RB; de Vries, TM; Eldon, MA; Koup, JR; Smithers, JA, 1998
)
2
"Procainamide is an effective antiarrhythmic that is often used to convert atrial fibrillation to normal sinus rhythm. "( Procainamide-induced postoperative pyrexia.
Murray, KD; Vlasnik, JJ, 1999
)
3.19
"Procainamide is a sodium channel blocker which prolongs QRS and QTc intervals, yet its major active metabolite, N-acetylprocainamide (NAPA), generally prolongs only QTc and has very different electrophysiologic and antiarrhythmic actions. "( Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
Funck-Brentano, C; Light, RT; Lineberry, MD; Roden, DM; Woosley, RL; Wright, GM, 1989
)
1.96
"Procainamide is a class I antiarrhythmic drug. "( Effects of therapeutic concentrations of procainamide on transmembrane action potentials of normal and infarct zone Purkinje fibers and ventricular muscle cells.
Dangman, KH; Miura, DS, 1989
)
1.99
"Procainamide is a commonly used antiarrhythmic drug associated with the induction of autoantibodies, and occasionally with a lupus-like syndrome."( Procainamide-induced lupus anticoagulants and thrombosis.
Currie, MS; Greenberg, CS; Li, GC, 1988
)
2.44
"Procainamide is a potent inducer of autoantibodies. "( Effects of long-term procainamide therapy on immunoglobulin synthesis.
Yu, CL; Ziff, M, 1985
)
2.03
"Procainamide-induced lupus is a well-recognized syndrome, but the events leading up to clinical symptoms are obscure. "( Serologic changes during induction of lupus-like disease by procainamide.
Curd, JG; Johnson, AD; Nusinow, SR; Rubenson, DS; Rubin, RL; Tan, EM, 1986
)
1.96

Effects

Procainamide has been a mainstay of treatment against acute and chronic supraventricular and ventricular arrhythmias for more than 30 years. It has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells.

ExcerptReferenceRelevance
"Procainamide has a high propensity for the induction of an autoimmune response. "( Autoallergic reactions induced by procainamide.
Rubin, RL; Tan, EM, 1984
)
1.99
"Procainamide has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells by reversing CpG island hypermethylation."( Procainamide is a specific inhibitor of DNA methyltransferase 1.
Lee, BH; Lin, X; Nelson, WG; Yegnasubramanian, S, 2005
)
2.49
"Procainamide (PA) has been a mainstay of treatment against acute and chronic supraventricular and ventricular arrhythmias for more than 30 years. "( Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
Giardina, EG, 1984
)
3.15
"Procainamide has a high propensity for the induction of an autoimmune response. "( Autoallergic reactions induced by procainamide.
Rubin, RL; Tan, EM, 1984
)
1.99
"Procainamide has become the most frequent cause of the drug-induced lupus syndrome. "( SLE: idiopathic or drug-induced?
Condemi, JJ, 1980
)
1.7
"Procainamide therapy has frequently been reported as a cause of agranulocytosis, but severe thrombocytopenia associated with the use of this drug has been noted only once. "( Procainamide-induced agranulocytosis and thrombocytopenia.
Amorosi, EL; Rothman, IK, 1979
)
3.15
"Procainamide has been used extensively for the treatment of ventricular arrhythmias. "( Procainamide inhibits sympathetic nerve activity in rabbits.
Cohen, MD; Dibner-Dunlap, ME; Thames, MD; Yuih, SN, 1992
)
3.17

Actions

ExcerptReferenceRelevance
"Procainamide (PA) may cause drug-induced lupus, and its reactive metabolites, hydroxylamine-PA (HAPA) and nitroso-PA, are held responsible for this. "( Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages.
Abel, J; Degen, G; Gleichmann, E; Goebel, C; Mittmann, S; Sachs, B; Schraa, S; Uetrecht, J; Vogel, C; Wulferink, M, 1999
)
3.19

Treatment

Procainamide inhibited the overexpression of DNMT1 and diminished the overproduction of IL-6 in rhabdomyolysis rats. Treatment with procainamide or atenolol was not effective.

ExcerptReferenceRelevance
"Procainamide treatment was introduced and the digestive symptoms improved."( [Encopresis revealing myotonic dystrophy in 2 children].
Avez-Couturier, J; Cuisset, JM; Dolhem, P; Gottrand, F; Lamblin, MD; Michaud, L; Turck, D; Vallée, L, 2009
)
1.07
"Procainamide treatment led to an equal, rate independent VERP and APD increase: no post repolarization refractoriness."( Rate dependent effects of procainamide on the threshold current for pacing in the setting of postrepolarization refractoriness in dogs.
den Dulk, K; Leerssen, HM; van der Zande, J; Vos, MA; Wellens, HJ, 1999
)
1.32
"Treatment with procainamide not only inhibited the overexpression of DNMT1 but also diminished the overproduction of IL-6 in rhabdomyolysis rats."( Therapeutic Effects of Procainamide on Endotoxin-Induced Rhabdomyolysis in Rats.
Chen, SJ; Hii, HP; Ka, SM; Liao, MH; Shih, CC; Tsao, CM; Wu, CC, 2016
)
1.08
"Treatment with procainamide or atenolol was not effective."( Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002
)
0.65
"Treatment with procainamide and quinidine, but not with disopyramide, protected alpha-adrenoceptors from persistent blockade by phenoxybenzamine; quinidine was far more effective than procainamide."( Influence of disopyramide, compared with procainamide and quinidine, on isolated dog arteries in response to transmural stimulation and norepinephrine.
Konishi, M; Miyazaki, M; Okunishi, H; Toda, N,
)
0.74

Toxicity

Procainamide hydrochloride was able to protect mice and rats from cisplatin-induced nephrotoxicity. Free radical processes are proposed to play a crucial role in the development of procainamide adverse effects.

ExcerptReferenceRelevance
"There is a narrow margin between therapeutic and toxic doses and serum levels of digitalis glycosides."( Digitalis toxicity.
Antman, EM; Smith, TW, 1985
)
0.27
" When this oxidation was minimized by rapid manipulations or inhibited by ascorbic acid, cytotoxicity was reduced or eliminated, suggesting that the nitroso-derivative may be the toxic metabolite."( Cytotoxicity of oxidative metabolites of procainamide.
Jones, JE; Rubin, RL; Uetrecht, JP, 1987
)
0.54
"To assess the efficacy, plasma drug concentrations and adverse effects of a new sustained release preparation of procainamide, 33 patients with heart disease were studied in an acute dose-ranging protocol and a chronic treatment protocol."( Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
Bigger, JT; Fenster, PE; Giardina, EG; Marcus, FI; Mayersohn, M; Perrier, D, 1980
)
0.7
" The comparison of hemodynamic, electrocardiographic and toxic effects of mexiletine with those produced by other antiarrhythmics showed that mexiletine placed itself among the better tolerated antiarrhythmics during the administration of progressively increasing doses."( Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics.
Carlier, J, 1980
)
0.26
" Transesophageal atrial pacing is a safe and effective means of terminating atrial flutter in the pediatric population."( Conversion of atrial flutter in pediatric patients by transesophageal atrial pacing: a safe, effective, minimally invasive procedure.
Rhodes, LA; Saul, JP; Walsh, EP, 1995
)
0.29
"Free radical processes are proposed to play a crucial role in the development of procainamide adverse effects."( Modulation of procainamide toxicity by selenium-enriched yeast in rats.
Danch, A; Drózdz, M; Kopieczna-Grzebieniak, E; Magner-Wróbel, K; Toborek, M, 1993
)
0.87
"We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT)."( Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.
Fujiki, A; Inoue, H; Tani, M; Yoshida, S, 1996
)
0.69
" No serious cardiac or noncardiac adverse events were noted during procainamide therapy, although there was a significant increase in the incidence of nausea."( Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery.
Buckley, MJ; DeSanctis, RW; Gold, MR; O'Gara, PT, 1996
)
0.84
" Hypotension was the major adverse effect seen with procainamide."( Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.
Carberry, PA; Dunn, GH; Kowey, PR; Lewis, WR; Perry, KT; Stambler, B; Vanderlugt, JT; Volgman, AS, 1998
)
0.78
" We propose that procainamide, after accumulation in the kidney, may coordinate with cisplatin to form a less toxic DPR-like complex that renders rats less susceptible to cisplatin-induced toxicity."( Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Cadoni, A; Cafaggi, S; Civalleri, D; Esposito, M; Lindup, WE; Lunardi, G; Mariggiò, MA; Pastrone, I; Tolino, G; Vannozzi, MO; Viale, M; Zicca, A, 2000
)
0.91
"In preceding papers, we proposed that procainamide hydrochloride, a class I antiarrhythmic agent, was able to protect mice and rats from cisplatin-induced nephrotoxicity and that it could exert its action through accumulation in kidneys followed by coordination with cisplatin (or its hydrolysis metabolites) and formation of a less toxic platinum compound similar to the new platinum(II) triamine complex cis-diamminechloro-[2-(diethylamino)ethyl 4-amino-benzoate, N4]-chlorideplatinum(II) monohydrochloride monohydrate, obtained by the reaction of cisplatin with procaine hydrochloride."( Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats.
Bocchini, V; Cafaggi, S; Caviglioli, G; Mariggiò, MA; Ottone, M; Vannozzi, MO; Viale, M; Zicca, A, 2002
)
0.85
" The toxicity of these compounds against hepatoma cells (MH3924A) and, to a lesser extent, against mouse fibroblast (NIH 3T3) and cervix carcinoma (HeLa) cells was also enhanced, but they were not as toxic as dacarbazine (HeLa)."( Alkylating benzamides with melanoma cytotoxicity.
Bauder-Wüst, U; Eisenhut, M; Haberkorn, U; Mier, W; Mohammed, A; Schönsiegel, F; Wolf, M, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Therapy with these agents is often complicated because of the presence of significant associated adverse effects, clinician unfamiliarity, variable dosing strategies, and the potential for drug-drug interactions."( Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide.
Mohrien, KM; Oliphant, CS; Samarin, MJ,
)
0.33

Pharmacokinetics

The pharmacokinetic profile and the cardiovascular actions of desethyl-N-acetylprocainamide (NAPADE) were studied in chloralose-urethane anesthetized dogs. Both effectively double the half-life of conventional oral procainamide to 6.

ExcerptReferenceRelevance
") bolus injections of procainamide (PA) to study its pharmacokinetic behavior and to determine the effect of urinary pH upon renal excretion."( Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
Baer, DT; Barkus, JC, 1977
)
2.01
" The plasma half-life during the beta-phase averages 3 hours."( Clinical pharmacokinetics of procainamide.
Karlsson, E,
)
0.42
" Data are lacking relating pharmacokinetic alterations to haemodynamic measurements in patients with cardiac failure."( Pharmacokinetics in patients with cardiac failure.
Benowitz, NL; Meister, W,
)
0.13
" A 2-compartment pharmacokinetic model with a third compartment for the saliva was used to fit the plasma, urine, and saliva data simultaneously."( Relationship between the pharmacokinetics and pharmacodynamics of procainamide.
Benet, LZ; Galeazzi, RL; Sheiner, LB, 1976
)
0.49
"Previous procainamide pharmacokinetic studies have involved the use of colorimetric and fluorimetric methods for the determination of drug concentrations in plasma and urine."( The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.
Christopher, GT; Cutler, RE; Levy, RH; Lindner, A; Simons, KJ, 1975
)
0.98
" Pharmacokinetic parameters were calculated with the aid of pharmacokinetics independent of the model principles."( [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
Gawrońska-Szklarz, B; Górnik, W; Kutrzeba, J; Wójcicki, J; Zakrzewski, J,
)
0.45
"The pharmacokinetic and pharmacodynamic profiles of procainamide (PA) and its major metabolite, acetylprocainamide (NAPA), were analyzed by extended combined pharmacokinetic and pharmacodynamic model in rabbits."( [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite].
Huang, SK; Liu, XQ, 1991
)
0.77
" Acecainide renal clearance, nonrenal clearance, steady-state volume of distribution, and other pharmacokinetic parameters were estimated using standard approaches."( Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
Boudoulas, H; Coyle, JD; Lima, JJ, 1991
)
0.28
" We analyzed the pharmacokinetic properties of PA and NAPA and elucidated their effect kinetics with a pharmacokinetic-pharmacodynamic (PK/PD) model in view of different transfer qualities."( [Combined pharmacokinetic-pharmacodynamic model of procainamide in rabbits with induced ventricular fibrillation threshold (VFT) changes].
Huang, SK; Lu, DY; Lu, H; Lu, JF; Yang, JY, 1991
)
0.53
"Disposition kinetics of procainamide (PA) and its metabolite N-acetylprocainamide (NAPA) in rats was simulataneously predicted by a physiological pharmacokinetic model."( [Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model].
Deng, N; Huang, SK; Liu, XD, 1991
)
0.84
" Pharmacokinetic evaluations in a renally compromised neonate confirmed that total PA clearance and the renal clearance of both PA and NAPA were reduced, although not to the extent expected for the degree of renal impairment."( Therapeutic monitoring and pharmacokinetic evaluation of procainamide in neonates.
Bryson, SM; Hosking, MC; Irwin, DB; Leson, CL; Trope, AE, 1991
)
0.53
" This was accomplished by generating parent drug and metabolite plasma level profiles assuming formation and excretion rate-limited pharmacokinetic models with absorption rate constants obtained from bivariate normal distributions and designated random errors."( The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.
Chen, ML; Jackson, AJ, 1991
)
0.28
" Blood and urine samples were obtained and pharmacokinetic parameters of procainamide were determined in each treatment period."( Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide.
Boyd, RA; Chang, D; Chin, SK; Giacomini, KM; Lam, YW, 1991
)
0.75
"Blood level studies were carried out in rats to determine the effects of chronic ethanol ingestion on the distribution pharmacokinetic parameters and tissue steady-state partition coefficients of procainamide."( Effects of chronic ethanol ingestion on pharmacokinetics of procainamide in rats.
Gole, DJ; Nagwekar, JB, 1991
)
0.71
" The reported concentrations and pharmacokinetic parameters are from the HPLC data unless otherwise indicated."( Concentration-dependent clearance of procainamide in normal subjects.
Boudoulas, H; Coyle, JD; Lima, JJ; Mackichan, JJ,
)
0.4
"The pharmacokinetic profile and the cardiovascular actions of desethyl-N-acetylprocainamide (NAPADE) were studied in chloralose-urethane anesthetized dogs."( Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog.
King, LW; Lertora, JJ, 1986
)
0.74
" In group 1, the elimination of procainamide was described by a 1-compartment, open pharmacokinetic model."( Pharmacokinetics of procainamide hydrochloride in dogs.
Brown, SA; Davis, CA; Davis, LE; McKiernan, BC; Papich, MG, 1986
)
0.88
" In these studies, we showed that NAPA has an elimination-phase half-life that is more than twice as long as procainamide and suggested that patient compliance and arrhythmia suppression might be improved if NAPA were used to circumvent the inconvenience of the frequent dosing schedule that has been recommended for procainamide."( Pharmacokinetics of N-acetylprocainamide.
Atkinson, AJ; Ruo, TI, 1986
)
0.78
" There were no significant differences in the mean pharmacokinetic parameters of procainamide and NAPA after ranitidine coadministration compared to base line."( Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated.
Ferguson, RK; Kosoglou, T; Rocci, ML; Vlasses, PH, 1989
)
0.74
" Trimethoprim may increase procainamide and N-acetylprocainamide plasma concentrations, resulting in increased pharmacodynamic response apparently caused by the competition for renal tubular cationic secretion."( Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
Andress, E; Chase, SL; Ferguson, RK; Greenspon, AJ; Kosoglou, T; Lottes, S; Rocci, ML; Vlasses, PH, 1989
)
0.83
" The mean area under the plasma concentration-time curve, elimination half-life or oral clearance of the morning and evening dosages did not differ."( Chronopharmacokinetic studies of pranoprofen and procainamide.
Ebihara, A; Fujimura, A; Kajiyama, H; Kumagai, Y; Nakashima, H; Sugimoto, K, 1989
)
0.53
" On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects."( Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Echt, DS; Roden, DM; Woosley, RL, 1986
)
0.27
" The temporal and static plasma concentration-effect relationships were evaluated by pharmacodynamic modeling and linear regression."( Pharmacodynamics of procainamide in patients with ventricular tachyarrhythmias.
Kates, RE; Liem, LB; Swerdlow, CD; Yee, YG, 1988
)
0.6
" Ethanol shortened biological half-life of procainamide elimination, increased the value of the rate constant of elimination and procainamide clearance."( The influence of ethanol on pharmacokinetic parameters of procainamide in rabbits.
Orszulak-Michalak, D; Polakowski, P, 1988
)
0.78
"The effects of amiodarone on the pharmacokinetic and electrophysiologic properties of procainamide were examined in eight patients treated for recurrent ventricular arrhythmias who received intravenous procainamide, 6 to 15 mg/kg, at control and after 1 to 2 weeks of oral amiodarone treatment."( Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide.
Heger, JJ; Miles, WM; Prystowsky, EN; Windle, J, 1987
)
0.73
"Abnormal procainamide pharmacokinetics (prolonged half-life and decreased volume of distribution) and pharmacodynamics (decreased threshold for the suppression of premature ventricular complexes) have been suggested in patients with acute myocardial infarction or congestive heart failure, or both."( Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure.
Estes, DM; Kayden, DS; Kessler, KM; Koslovskis, PL; Myerburg, RJ; Palomo, AR; Sequeira, R; Trohman, RG, 1986
)
2.13
" Substantial differences in pharmacokinetic parameters of PA depending on acetylation phenotype were found."( Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
Grześkowiak, A; Lowicki, Z; Michałowska, D; Ochotny, R; Tomaszkiewicz, T; Wierzchowiecki, M, 1980
)
0.56
" This review addresses the clinical pharmacokinetic aspects of drug therapy in haemodialysis patients and considers: (a) the effects of ESRD on the general pharmacokinetics of drugs; (b) dialysis clearance and its impact on drug and metabolite elimination; (c) the definition of dialysability and the criteria for evaluation of drug dialysability; (d) pharmacokinetic parameters which are useful in the prediction of drug dialysability; and (e) the application of pharmacokinetic principles to the adjustment of dosage regimens in haemodialysis patients."( Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
Lee, CS; Marbury, TC,
)
0.13
"Routine clinical pharmacokinetic data collected from patients receiving procainamide were analysed to estimate population pharmacokinetic parameters."( Population pharmacokinetics of procainamide from routine clinical data.
Grasela, TH; Sheiner, LB,
)
0.65
" The therapeutic dose, clearance, extraction coefficient, bioavailability and half-life are the object of particular study."( [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
Bricaud, H; Lévy, RH; Lévy, S, 1980
)
0.26
" Pharmacokinetic analysis via the two-compartment open model showed that bile duct ligation caused a decrease in overall clearance from approximately 61."( Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction.
Basseches, PJ; DiGregorio, GJ, 1982
)
0.59
" The plasma concentrations of PA and N-acetylprocainamide (NAPA) as well as the pharmacodynamic effect (prolongation of the QT interval) were monitored."( The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration.
Duran, SH; Ellis, EJ; Malloy, M; Ravis, WR; Smyth, BG, 1994
)
0.81
" Drugs characterized by low accumulation indices (AI) showed virtually no change in the 90% confidence interval (CI) of AUC and CMAX upon multiple dosing."( Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.
el-Tahtawy, AA; Jackson, AJ; Ludden, TM, 1994
)
0.29
" The pharmacokinetic data analysis used a compartment model independent approach."( Pharmacokinetics of sematilide in renal failure.
Dandekar, KA; Gehr, TW; Hinderling, PH; Ripley, E; Shi, J; Sica, DA, 1996
)
0.29
" Blood and urine samples were obtained and pharmacokinetic parameters for procainamide were determined for each treatment period."( Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide.
Cascio, W; Griener, J; Martin, DE; Patterson, JH; Raasch, R; Shen, J, 1996
)
0.76
" However, the following main changes in N-acetylprocainamide (metabolite) pharmacokinetic parameters were found: 1) increase of the penetration rate constants between the compartments and mean residence time during propofol anesthesia 2) prolongation of the mean residence time during thiopental anesthesia 3) increase of mean residence time of N-acetylprocainamide during anesthesia with ketamine, pentobarbital or propofol."( The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide.
Orszulak-Michalak, D,
)
0.59
"Although no antiarrhythmic agent has ideal pharmacokinetic and pharmacodynamic characteristics, it is useful to evaluate antiarrhythmic agents in terms this ideal profile."( Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.
Nolan, PE,
)
0.13
" Procainamide and NAPA pharmacokinetic parameters observed after administration of Procanbid tablets were similar in blacks and whites, and in men and women."( Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
Abel, RB; de Vries, TM; Eldon, MA; Koup, JR; Smithers, JA, 1998
)
1.47
" Noncompartmental analysis was performed to estimate the pharmacokinetic parameters."( The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide.
Adekoya, F; Eddington, ND; Kharidia, J, 1998
)
0.53
" Also some other drugs may change pharmacokinetics of procainamide, for example the iv anesthetics influence on pharmacokinetic parameters of procainamide."( Influence of midazolam on pharmacokinetic parameters of procainamide in rabbits.
Orszulak-Michalak, D; Owczarek, J; Wiktorowska-Owczarek, AK,
)
0.63
"The pharmacokinetic profile of cisplatin administered either in the presence or absence of procainamide hydrochloride was investigated in BDF1 female mice bearing 6-day P388 leukemia."( Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Cafaggi, S; Cilli, M; Lindup, E; Mariggiò, MA; Ottone, M; Parodi, B; Vannozzi, MO; Viale, M,
)
0.57
"The combined administration of the antiarrhythmic drug and cisplatin caused significant differences in the pharmacokinetic profiles of Pt in plasma, ascites fluid and tissues."( Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Cafaggi, S; Cilli, M; Lindup, E; Mariggiò, MA; Ottone, M; Parodi, B; Vannozzi, MO; Viale, M,
)
0.35
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The validated method was successfully applied to a pharmacokinetic study after per os administration of nicorandil in rats."( Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study.
Araujo, DP; Bastos, LF; César, IC; Coelho, Mde M; de Fátima, Â; Godin, AM; Guidine, PA; Pianetti, GA, 2011
)
0.37
" The method was found to be suitable for the quantification of atenolol in a pharmacokinetic study after a single oral administration of 100 mg atenolol to 18 healthy subjects."( Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study.
Niopas, I; Spanakis, M, 2013
)
0.39
" Pharmacokinetic analysis of procainamide and its metabolite, N-acetylprocainamide (NAPA), was performed using serum and urine specimens."( Procainamide pharmacokinetics during extracorporeal membrane oxygenation.
Rosenbaum, AN; Vollmer, NJ; Wieruszewski, PM; Wittwer, ED, 2023
)
2.64

Compound-Compound Interactions

The study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence. However, higher propafenone doses were necessary during monotherapy.

ExcerptReferenceRelevance
" The binding of digitoxin and cardioactive metabolites to serum proteins was studied using equilibrium dialysis (an in vitro chemical assay) alone and in combination with a modified 86Rb method."( Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin.
Storstein, L, 1976
)
0.26
"The efficacy of mexiletine used alone, and in combination with a class Ia antiarrhythmic drug, was assessed in 159 previously drug-refractory patients with ventricular tachycardia (VT) during serial electrophysiologic studies and during long-term (5-year) clinical follow-up."( Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
Garan, H; McElroy, M; McGovern, B; Newell, JB; Ruskin, JN; Schoenfeld, MH; Whitford, EG, 1988
)
0.27
" We examined the efficacy and electrophysiology of 110 antiarrhythmic drug combination trials at electrophysiologic study in 74 patients with recurrent ventricular tachycardia."( Antiarrhythmic drug combinations in the treatment of ventricular tachycardia.
Echt, DS; Griffin, JC; Keefe, DL; Mason, JW; Ross, DL; Swerdlow, CD; Sze, DY; Winkle, RA, 1982
)
0.26
"This study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence and prospectively evaluated the ability of the drug combination to prevent ventricular tachycardia recurrence when the arrhythmia remained inducible but was modified."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
0.51
" Among patients in whom this drug combination was unsuccessful at electrophysiologic study (group III) and in those who received alternative therapy after combination therapy was discontinued because of side effects, actuarial recurrence rates were 9%, 14% and 32% at 1, 2 and 3 years, respectively."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
0.29
" This drug combination deserves further evaluation."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
0.29
" The mechanisms underlying the efficacy of this drug combination have not been fully elucidated."( Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Dorian, P; Ham, M; Lee, SD; Newman, D, 1997
)
0.3
"The drug-drug interactions between antiarrhythmic drugs were studied in chick embryos."( Drug-drug interactions between antiarrhythmic drugs in chick embryos.
Kanke, M; Sugiyama, T; Tsuchimoto, K; Yoshiyama, Y, 2004
)
0.32
" The drug-drug interaction (DDI) potential of these drugs for the hOCT/rOct-mediated hepatic/renal uptake process was also assessed."( Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions.
Iwatsubo, T; Kamimura, H; Noguchi, K; Umehara, KI; Usui, T, 2008
)
0.35
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

St John's wort has an acute effect to increase bioavailability of procainamide. Cimetidine decreased renal clearance by 36% and decreased the ratio of systemic clearance ofprocainamide to bioavailability by 28%. Essential structural elements seem to determine a better bioavailability.

ExcerptReferenceRelevance
" In contrast to these results, compounds such as urea and amitrole, which remain completely nonionized over the pH range studied, showed no change in absorption rate when the pH was varied."( Lung pH and pulmonary absorption of nonvolatile drugs in the rat.
Less, MJ; Schanker, LS,
)
0.13
" In contrast hydralazine affects not only PA acetylation but also its absorption rate and transformation by other metabolic pathways."( The effect of isoniazid and other drugs on the acetylation of procainamide in the intact rat.
Hayes, AH; Schneck, DW; Sprouse, JS, 1978
)
0.5
" The bioavailability of the oral preparations (versus intravenous) averaged 83% for the capsule and 79% for the sustained-release tablet."( Absorption kinetics of procainamide in humans.
Baer, DT; Lalka, D; Manion, CV; Meyer, MB, 1977
)
0.57
" The bioavailability of procainamide appears not to be significantly altered by taking an oral dose with food."( The effect of food on procainamide absorption.
McKnight, WD; Murphy, ML, 1976
)
0.88
" Absolute bioavailability was determined by a new stable isotope method that entailed intravenous injection of NAPA 13C at the same time that an unlabeled NAPA capsule was given orally."( Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.
Atkinson, AJ; Dutcher, JS; Lee, WK; Strong, JM, 1975
)
0.52
" This was accomplished by generating parent drug and metabolite plasma level profiles assuming formation and excretion rate-limited pharmacokinetic models with absorption rate constants obtained from bivariate normal distributions and designated random errors."( The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.
Chen, ML; Jackson, AJ, 1991
)
0.28
" Essential structural elements seem to determine a better bioavailability than procainamide: character of the substitution (in para) of the benzenic cycle; length of the lateral chain."( A new series of antiarrhythmic procainamide derivatives: toxicity and activity-simulated passive absorption relation.
Arnould-Guérin, ML; Brazier, M; Lefebvre, C; Nguyen-Tri-Xuong, E; Pieri, F; Reynaud, P; Robert, H, 1990
)
0.79
" Cimetidine significantly increased the procainamide area under the serum concentration-time curve by 43%, decreased renal clearance by 36%, and decreased the ratio of systemic clearance of procainamide to bioavailability by 28%."( Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine.
Gallastegui, J; Jung, D; Paloucek, FP; Rodvold, KA, 1987
)
0.83
" In the first (pranoprofen) study, the mean time to maximum concentration was significantly shorter, and the mean maximum plasma concentration as well as absorption rate constant had a tendency to be greater after the morning than after the evening trial."( Chronopharmacokinetic studies of pranoprofen and procainamide.
Ebihara, A; Fujimura, A; Kajiyama, H; Kumagai, Y; Nakashima, H; Sugimoto, K, 1989
)
0.53
"The bioavailability characteristics of two sustained-release oral procainamide preparations, Procan SR and Pronestyl-SR, were compared in 10 patients with arrhythmias."( Comparative bioavailability of two oral sustained-release procainamide products.
A'Zary, E; Baker, BA; Bodenheimer, MM; Gleckel, L; Reynolds, JR, 1988
)
0.76
"Simulated data using a linear one- and two-compartment body model with different absorption characteristics were used to evaluate the ability of single dose bioavailability data to predict the relationships that exist at steady state."( Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics.
Jackson, AJ,
)
0.13
" Method A also used an absorption rate constant."( Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
Chow, MS; DiPersio, DM,
)
0.47
" PA's clinical pharmacology has been studied extensively and its bioavailability (75-95%); volume of distribution (1."( Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
Giardina, EG, 1984
)
1.71
"The purpose of this study was to determine the bioavailability of N-Acetylprocainamide (NAPA) from mixed diet in rats."( Bioavailability of N-acetylprocainamide from mixed diet in rats.
Durrani, M; Gupta, SD; Kamath, BL; Lai, CM; Stampfli, H; Yacobi, A, 1981
)
0.79
" A substantial degree of interpatient and intrapatient variability in the absorption rate for NAPA was observed."( N-Acetylprocainamide kinetics and clinical response during repeated dosing.
Cohen, J; Gaarder, T; Hurst, A; Jelliffe, RW; Rodman, JH, 1982
)
0.7
" The elimination rate constant, clearance, and absolute bioavailability of the drug (determined by AUC measurements and the amounts excreted unchanged in the urine) decreased significantly with age."( Age-related pharmacokinetics of N-acetylprocainamide in rats.
Kamath, BL; Lai, CM; Look, ZM; Stampfli, HF; Yacobi, A, 1983
)
0.53
"Thin-layer chromatographic methods were applied for bioavailability studies of procainamide in serum and urine."( Thin-layer chromatographic determination of procainamide and N-acetylprocainamide in human serum and urine at single-dose levels.
Kark, B; Keller, A; Sistovaris, N, 1983
)
0.75
"The influence of aluminium hydroxide and magnesium oxide on the oral bioavailability of quinidine, procainamide and propranolol in the dog was investigated."( Interaction of antacids with antiarrhythmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs.
Belpaire, F; Braeckman, P; Remon, JP; Van Severen, R, 1983
)
0.69
" The therapeutic dose, clearance, extraction coefficient, bioavailability and half-life are the object of particular study."( [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
Bricaud, H; Lévy, RH; Lévy, S, 1980
)
0.26
" In contrast to MCA, declopramide has a rapid clearance from serum, a lower tissue concentration (about 15-fold lower than MCA) and a lower oral bioavailability (about 6-fold lower than MCA)."( Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice.
Hua, J; Kane, R; Pero, RW, 1999
)
0.53
" declopramide administered orally at 40 mg/kg gave the same efficacy of inhibiting tumor growth as im injection although oral administration had a lower bioavailability due to the formulation of N-acetyl-declopramide."( Comparison of antitumor activity of declopramide (3-chloroprocainamide) and N-acetyl-declopramide.
Bryngelsson, C; Hua, J; Kane, R; Pero, RW; Sheng, Y,
)
0.38
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" In a separate experiment when mice were fed purified hypericin, the active component of St John's wort, a significant increase in bioavailability (53%) of procainamide was observed compared with the control group."( Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice.
Actor, JK; Dasgupta, A; Hovanetz, M; Olsen, M; Wells, A, 2007
)
0.76
"St John's wort has an acute effect to increase bioavailability of procainamide but has no effect on its metabolism."( Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice.
Actor, JK; Dasgupta, A; Hovanetz, M; Olsen, M; Wells, A, 2007
)
0.8
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The aim of the present study was to examine the variability of bioavailability (F) of bisoprolol in routinely treated Japanese patients and intestinal absorption characteristics of the drug."( Variability of bioavailability and intestinal absorption characteristics of bisoprolol.
Fujii, N; Hashimoto, Y; Horie, A; Inoue, H; Ishida, K; Nishimura, M; Nozawa, T; Taguchi, M, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A simple and rapid spectrophotometric procedure has been developed for the determination of four local anaesthetics containing a free primary amine moiety. N-acetylprocainamide (NAPA) was detected in serum samples obtained soon after procainamide dosing.

ExcerptRelevanceReference
" Samples were obtained at times chosen to approximate the maximum and minimum serum concentrations of the drug during a dosing interval."( pH-dependent secretion of procainamide into saliva.
Goldfarb, AL; Jusko, WJ; Koup, JR, 1975
)
0.55
" At a dosage of 80 mg/d (20 mg every six hours) a significant reduction in ventricular extrasystoles was demonstrated on 20 separate occasions."( [Effect of prajmalium bitartrate and procaine amide on ventricular extrasystoles (author's transl)].
Bussmann, WD; Kaltenbach, M; Müller, E, 1976
)
0.26
" The method was successfully applied to commercially available dosage forms."( Rapid fluorometric determination of procainamide hydrochloride dosage forms.
Beiser, C; TTan, HS, 1975
)
0.53
" The basic principles of pharmacokinetics are outlined and their application to the design of dosage regimens described."( Pharmacokinetics of antiarrhythmic drugs.
Shand, DG; Woosley, RL, 1978
)
0.26
" It is important to know how the pharmacokinetics of a drug vary with different disease states so that appropriate adjustments to dosage can be made."( Series on pharmacology in practice. 2. Antiarrhythmic drug therapy.
Federman, J; Vlietstra, RE, 1979
)
0.26
" The dose-response relationship revealed that procaine inhibited the resting membrane conductance almost completely in a one-to-one manner with the dissociation constant of about 1 mM."( The effect of procaine on the passive electrical properties of guinea-pig ventricular muscle.
Hashimoto, K; Ochi, R, 1978
)
0.26
" It is concluded that at therapeutic dosage disopyramide does not present deleterious hemodynamic effects in animals and proves to be a valid alternative to other traditional antiarrhythmic agents."( [Hemodynamic effects of disopyramide and procainamide in open-chest animals].
Binetti, G; Branzi, A; Magelli, C; Magnani, B; Malini, PL; Specchia, S; Zannoli, R, 1978
)
0.52
" By these mechanisms, cardiac failure potentially affects absorption and disposition characteristics of drugs, which may necessitate adjustment in dosage regimen for optimum therapy."( Pharmacokinetics in patients with cardiac failure.
Benowitz, NL; Meister, W,
)
0.13
" An attempt to reduce the drug dosage should be made every 6 months, in hospital."( [Ventricular tachycardia of the infant. 2 new cases].
Bricaud, H; Choussat, A; Clémenty, J; Dallocchio, M; Giraudet, C; Saint-Martin, J, 1976
)
0.26
" Inadequate blood levels may be predicted from a single blood level eight hours after the first dose, which could allow for dosage adjustment."( Procaineamide blood levels after administration of a sustained-release preparation.
Cunningham, E; Sloman, G, 1977
)
0.26
" The initial effect of procainamide (10(-6) to 10(-3) mol/litre) was to produce a prompt reduction of the passive Na influx, dose-dependent along a sigmoid log dose-response curve."( Influence of procainamide on sodium and potassium exchange and permeabilities in cultured human cells.
McCall, D, 1976
)
0.94
" 3 These results confirm the feasibility of using a sustained-release procainamide preparation, such as Cardiorytmin Retard, since it would be possible to administer the same amount of drug in fewer daily doses without plasma concentrations becoming ineffective towards the end of each dosing interval."( Procainamide absorption studies to test the feasibility of using a sustained-release preparation.
Hamer, J; Kaspi, T; Kaye, CM; Kumana, CR; Padgham, C; Shaw, TR, 1975
)
1.93
" The presence of PG generally enhanced the absorption of each drug, and the degree of enhancement appeared to be related to the percentage of PG in the dosing solution."( Propylene glycol as a vehicle for percutaneous absorption of therapeutic agents.
Bailey, DN,
)
0.13
" The determination of nitroprocainamide (NPA), a stable decomposition product of the reactive hydroxylamine and nitroso species, in the urine of rats dosed with procainamide is reported here using the sensitive and selective method of HPLC with electrochemical detection."( Determination of metabolically derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection.
Adams, LE; Heineman, WR; Hess, EV; Mongey, AB; Roberts, SM; Wheeler, JF,
)
0.69
"A simple and rapid spectrophotometric procedure has been developed for the determination of four local anaesthetics containing a free primary amine moiety and of procainamide hydrochloride as the drug substances and in dosage forms."( Use of 7,7,8,8-tetracyanoquinodimethane for spectrophotometric determination of certain local anaesthetics and procainamide hydrochloride.
Hassan, HY; Hussein, SA; Mohamed, AM; Mohamed, HA, 1991
)
0.69
" The effect of procainamide on the anterograde effective refractory period of the accessory pathway was dose dependent; patients who lost preexcitation had a steeper dose-response curve."( Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.
Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990
)
0.96
"2 ml/min, was less than half that observed in healthy adults suggesting markedly reduced dosage requirements."( Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
Beirne, GJ; Moorthy, AV; Raehl, CL, 1986
)
1.71
" In these studies, we showed that NAPA has an elimination-phase half-life that is more than twice as long as procainamide and suggested that patient compliance and arrhythmia suppression might be improved if NAPA were used to circumvent the inconvenience of the frequent dosing schedule that has been recommended for procainamide."( Pharmacokinetics of N-acetylprocainamide.
Atkinson, AJ; Ruo, TI, 1986
)
0.78
" Such a test was needed to evaluate the pharmacokinetic characteristics of controlled-release dosage forms characterized by long half-lives at low plasma concentration."( More-sensitive enzyme-multiplied immunoassay technique for procainamide and N-acetylprocainamide in plasma, serum, and urine.
Dhruv, RA; Henry, PR, 1988
)
0.52
" Although the greater bioequivalence, lesser variability, and the greater number of tablet dosage sizes would favor product A, patients stabilized on a particular brand of sustained-release procainamide should not be switched to another product without careful monitoring."( Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
Destache, CJ; Hilleman, DE; Mohiuddin, SM; Ortmeier, BG; Patterson, AJ,
)
0.56
" The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19."( Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
Andress, E; Chase, SL; Ferguson, RK; Greenspon, AJ; Kosoglou, T; Lottes, S; Rocci, ML; Vlasses, PH, 1989
)
0.75
"5 and 3 g every 8 hours resulted in systematic underprediction of observed concentrations at the two highest oral dosing rates."( N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
Crawford, MH; Kennedy, GT; Ludden, TM,
)
0.57
" Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level."( Antiarrhythmic drug therapy. Recent advances and current status.
Somberg, J, 1985
)
0.27
" Currently available sustained-release preparations provide the same therapeutic benefit with a more tolerable dosage schedule."( Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
Levin, BK; McGeehin, FC; Michelson, EL, 1988
)
0.55
" These findings indicate that with a procainamide dosing method commonly used during electropharmacologic testing, the plasma procainamide concentration decreases significantly during the first 15 minutes after the loading dose is administered."( Pharmacodynamics of intravenous procainamide as used during acute electropharmacologic testing.
Annesley, T; De Buitleir, M; Kou, WH; Kushner, JA; Morady, F; Nelson, SD; Schmaltz, S, 1988
)
0.83
" The initial drug was continued for 48 hours (eight doses), at which time the second drug, given at the same dosage and dosing interval, was substituted for a 48-hour period."( Comparative bioavailability of two oral sustained-release procainamide products.
A'Zary, E; Baker, BA; Bodenheimer, MM; Gleckel, L; Reynolds, JR, 1988
)
0.52
" As a consequence of Tmax and Cmax decreasing and increasing from single to multiple dosing regimens, the confidence intervals for these parameters reflected these changes."( Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics.
Jackson, AJ,
)
0.13
" Minor reactions were defined as those that required dosage reduction and major reactions as those that required drug discontinuation or permanent pacing for bradycardia."( Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias.
Cook, TS; DiMarco, JP; Nygaard, TW; Sellers, TD, 1986
)
0.27
" This could be attributed to a relatively low dosage and slow infusion speed."( Effects of four antiarrhythmic drugs on the induction and termination of paroxysmal supraventricular tachycardia.
Ishinaga, T; Komatsu, C; Tateishi, O; Tokuhisa, Y; Yoshimura, S, 1986
)
0.27
" A similar gene dose-response relationship was exhibited by the polymorphic N-acetyltransferase enzyme toward isoniazid and procainamide."( Biochemical investigation of the basis for the genetic N-acetylation polymorphism in the inbred hamster.
Ferguson, RJ; Hein, DW; Kirlin, WG; Weber, WW, 1985
)
0.48
" A thorough understanding of the applied pharmacology, dosage recommendations, toxicity, and practical considerations must be attained before these drugs can be used effectively."( Pharmacology and pharmacokinetics of drugs used to treat cardiac disease in horses.
McGuirk, SM; Muir, WW, 1985
)
0.27
" Furthermore, the reduction of procainamide dosing in patients with acute myocardial infarction or congestive heart failure, based solely on prior kinetic data, may result in inappropriate antiarrhythmic therapy."( Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure.
Estes, DM; Kayden, DS; Kessler, KM; Koslovskis, PL; Myerburg, RJ; Palomo, AR; Sequeira, R; Trohman, RG, 1986
)
2
"Flecainide was initially prescribed at a dose of 200 mg twice daily, but after early toxicity in patients with ventricular tachycardia (VT), the dosage was reduced to 100 mg twice daily."( Flecainide: long-term treatment using a reduced dosing schedule.
Flowers, D; Miura, D; O'Gallagher, D; Somberg, JC; Torres, V, 1985
)
0.27
"Two methods of predicting plasma procainamide concentrations (PPCs) for a sustained-release procainamide (SRP) dosage form were compared using previously published data on 12 healthy subjects."( Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
Chow, MS; DiPersio, DM,
)
0.75
"The utility of the antiarrhythmic drug procainamide (PA) is limited by the required dosage schedule (every three to four hours)."( Sustained-release procainamide: use of serum concentrations to determine dosage.
Cooper, MW; Reed, WE, 1985
)
0.87
" The dose-response and time-action parameters of the cardiac antiarrhythmic protection afforded by the prototype drugs and their acryloyl derivatives against chloroform-hypoxia-induced cardiac arrhythmias in unanesthetized mice and epinephrine-induced arrhythmias in alpha-chloralose anesthetized cats were determined."( Prolongation of procaine's and procainamide's actions by binding to acryloyl polymers.
Baker, T; Erker, EF; Okamoto, M; Riker, WF; Udenfriend, S, 1985
)
0.56
" Special consideration, however, must be given with regard to drug selection and dosage in order to avoid adverse effects on the mother and fetus."( Antiarrhythmic drug therapy during pregnancy.
Elkayam, U; Frishman, W; Rotmensch, HH, 1983
)
0.27
" If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate."( New directions in antiarrhythmic drug therapy.
Somberg, JC, 1984
)
0.27
" An extensive trial design incorporated the approaches of (1) generation of dose-response relations, (2) randomized crossover, and (3) prolonged electrocardiographic monitoring."( Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
Higgins, SB; Oates, JA; Reele, SB; Roden, DM; Smith, RF; Wilkinson, GR; Woosley, RL, 1980
)
0.5
" Thus, the dosage of procainamide must be individualized for both overall renal function (GFR) and the age-related variations in renal tubular secretion that are of most note in children and the elderly."( Aging and renal clearance of procainamide and acetylprocainamide.
Camacho, M; Drayer, DE; Kluger, J; Reidenberg, MM, 1980
)
0.87
" The initial dosage of NAPA was 500 mg every 8 hours, which was increased by 500 mg increments every few days until 90 percent suppression of arrhythmia or intolerable adverse effects occurred."( Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
Jaillon, P; Kates, RE; Peters, F; Winkle, RA, 1981
)
0.5
" Drug fever developed in one patient, and another had a mild recurrence of lupus symptoms during high-dose acetylprocainamide therapy that regressed with dosage reduction."( Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
Drayer, DE; Kluger, J; Lahita, R; Reidenberg, MM, 1981
)
0.95
"With ordinary procainamide tablets a dosing interval of 3-4 hours must be chosen to achieve therapeutically useful plasma concentrations during the entire interval."( [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
Galeazzi, RL; Karlaganis, G; Pirovino, M, 1980
)
0.87
" Symptomatic effects were common, with seven patients requiring a reduction in dosage or discontinuation of therapy."( Long-term antiarrhythmic therapy with acetylprocainamide.
Drayer, DE; Kluger, J; Leech, S; Lloyd, V; Reidenberg, MM, 1981
)
0.52
" Disopyramide at high concentrations potentiated the contractile response of mesenteric arteries to norepinephrine and tyramine, while, in contrast, procainamide and quinidine shifted the dose-response curve for norepinephrine to the right."( Influence of disopyramide, compared with procainamide and quinidine, on isolated dog arteries in response to transmural stimulation and norepinephrine.
Konishi, M; Miyazaki, M; Okunishi, H; Toda, N,
)
0.6
"In six normal subjects and 6 patients with primary cardiomyopathy, left ventricular performance was evaluated at rest and during isometric handgrip exercise after 4 days of oral N-acetylprocainamide (NAPA) at each of the three dosage levels (3, 4, 5, and 6 gm/day)."( Hemodynamic effects of N-acetylprocainamide in heart disease.
Amon, KW; Crawford, MH; Kennedy, GT; Ludden, TM; O'Rourke, RA; Sodums, MT, 1982
)
0.74
"Despite widespread marketing of a sustained release preparation of procainamide hydrochloride (PROCAN-SR, Parke-Davis), published literature demonstrating its efficacy in maintaining uniform serum drug levels over a 6-hour dosing interval is derived from only normal healthy volunteers."( Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
Mirando, T; Zema, MJ, 1983
)
0.71
" The clinical implications from this study necessitate dosage adjustments of procainamide in patients being concomitantly treated with cimetidine."( Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.
Heinzow, B; McLean, A; Somogyi, A, 1983
)
0.88
" The trend of nonlinearity may be more evident on chronic dosing of the drug when accumulation sets in."( Kinetics of procainamide N-acetylation in the rat in vivo and in the perfused rat liver preparation.
Cherry, WF; Fayz, S; Finkle, C; Huang, JC; Kong, P; Pang, KS,
)
0.51
" Because of the impaired renal function in ESRD patients, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs and active metabolites with extensive renal excretion."( Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
Lee, CS; Marbury, TC,
)
0.13
"Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs."( Reliability of antiarrhythmic drug plasma concentration monitoring.
Follath, F; Ganzinger, U; Schuetz, E,
)
0.13
" Medication dosages, dosing intervals, and time elapsed from last dosage until blood sampling were determined."( Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance.
Fuster, V; Goldman, ME; Kupersmith, J; Schweitzer, P; Squire, A; Stern, EH, 1984
)
0.27
" The patients received the appropriate dosage for 7 or more days before repeat radionuclide angiography was performed."( Effects on ventricular function of disopyramide, procainamide and quinidine as determined by radionuclide angiography.
Gebhardt, VA; Goddard, MD; Gryfe-Becker, B; Nichol, PM; Prato, FS; Rechnitzer, PA; Wisenberg, G; Zawadowski, AG, 1984
)
0.52
"A patient with chronic renal failure who experienced symptomatic ventricular tachycardia was treated successfully with procainamide (PA) after numerous dosage adjustments to optimize his clinical response and serum PA and NAPA concentrations."( High-dose procainamide in chronic renal failure.
Batenhorst, RL; Bottorff, MB; Kuo, CS, 1983
)
0.88
" Fifty-one weanling Hartley guinea pigs were divided into five groups which received either procainamide, hydralazine, acetanilide, caffeine or saline sc for 55 weeks; drug dosage was 10 mg/kg initially and was increased incrementally to 40 mg/kg by 10 months except for hydralazine, which was increased to 20 mg/kg."( Drug-induced antinuclear antibodies in the guinea pig.
Balazs, T; Robinson, CJ, 1982
)
0.48
" Serum level determinations can also be useful for establishing the best individual dosage of benzodiazepines, phenothiazines, and tricyclic antidepressants."( Serum drug concentrations in clinical perspective.
Koch-Weser, J, 1981
)
0.26
" Its short half-life of elimination requires a dosing frequency of every 3 hours with regular dosage forms or every 6-8 hours with a sustained action dosage."( Pharmacokinetics of a sustained release procainamide preparation.
Flanagan, AD, 1982
)
0.53
" N-acetylprocainamide (NAPA) was detected in serum samples obtained soon after procainamide dosing and peak concentrations were attained at 1 to 2 hr."( Procainamide elimination kinetics in pediatric patients.
Casta, A; Gelband, H; Kessler, K; Mehta, AV; Pickoff, AS; Singh, S, 1982
)
2.12
" Intravenous magnesium should be administered to newborns with acquired torsade de pointes; dosing guidelines for its use are suggested."( Effective use of magnesium for acquired torsade de pointes in a 4-month-old infant.
Bauman, JL; Bell, D; Mander, G; Thoele, DG,
)
0.13
"The frequency-dependent electrophysiologic effects of sematilide (n = 11) and amiodarone (n = 22) were determined at (1) drug-free baseline, (2) during steady-state (> 48 hours) dosing with sematilide (455 +/- 5 mg/d [mean +/- SEM]) or after 10."( The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Follmer, C; Godfrey, R; Pruitt, C; Sager, PT; Uppal, P, 1994
)
0.29
"Although intravenously administered procainamide has been used extensively during electropharmacologic testing for more than 10 years, there is little information available on the effects of incremental dosing of procainamide in patients with inducible, monomorphic ventricular tachycardia (VT)."( Effects of incremental doses of procainamide in patients with sustained uniform ventricular tachycardia.
Cho, JG; Grimm, W; Marchlinski, FE, 1994
)
0.85
" Five (17%), 7 (24%), and 1 (7%) patients, respectively, had no inducible sustained VT following the incremental dosing of procainamide."( Effects of incremental doses of procainamide in patients with sustained uniform ventricular tachycardia.
Cho, JG; Grimm, W; Marchlinski, FE, 1994
)
0.78
"Similar serum procainamide concentrations before and after programmed stimulation can be achieved at the described dosing regimen."( Effects of incremental doses of procainamide in patients with sustained uniform ventricular tachycardia.
Cho, JG; Grimm, W; Marchlinski, FE, 1994
)
0.93
"To evaluate the effects of programmed ventricular stimulation on resultant plasma concentrations of intravenously administered procainamide, drug dosing was performed with and without ventricular stimulation on two separate days (48 hours apart) in 12 dogs (13 dosing trials) at > or = 14 days after myocardial infarction (mean: 62 days)."( The effects of programmed ventricular stimulation on plasma procainamide levels: an experimental model.
Brautigam, RT; Kutalek, SP; Porter, S, 1994
)
0.74
" PD measurements (PQ, QS, QR, QT, RR, and HR) were collected prior to dosing and over a 24 h period."( Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide.
Eddington, ND; Kharidia, J, 1996
)
0.51
" The dose-response curves of adenosine on AV nodal conduction were almost identical in the control state and after verapamil, propranolol, or procainamide injection."( Effects of verapamil, propranolol, and procainamide on adenosine-induced negative dromotropism in human beings.
Lai, WT; Lee, CS; Sheu, SH; Wu, JC; Wu, SN, 1996
)
0.76
"The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1996
)
0.54
" Procainamide was received for 4 days; the dosage was adjusted for body weight."( Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery.
Buckley, MJ; DeSanctis, RW; Gold, MR; O'Gara, PT, 1996
)
1.51
" Procainamide dosage reduction may not be necessary in patients with chronic stable CHF who are receiving medical therapy."( Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy.
Acciaioli, J; Borzak, S; Krepostman, A; Padhi, ID; Rudis, MI; Svensson, CK; Tisdale, JE; Ware, JA; Webb, CR; Zarowitz, BJ, 1996
)
1.56
" The current sustained-release formulation requires 6-hour dosing (qid)."( Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators.
Haber, HE; Kerin, NZ; Meengs, WL; Salerno, D; Singer, RM; Timmis, GC, 1997
)
0.61
" A new sustained-release formulation, Procanbid, which allows for twice-daily dosing was recently approved for marketing in the United States."( Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
Abel, RB; de Vries, TM; Eldon, MA; Koup, JR; Smithers, JA, 1998
)
0.56
" On the other hand, the combined treatment with these two drugs induced effective anti-tumour efficacy in the relative mean tumour weight ratio (TRW/CRW), mean tumour weight and the survival rate compared with the control and each monotherapy, especially in the administration of Procainamide dosed at 30 mg/kg."( [Study on the combined therapy of DNA-methyltransferase inhibitor and interferon-alpha/beta for mouse spontaneously arose renal cell carcinoma, and immunological mechanism induced by the therapy].
Abe, K; Asano, K; Goto, H; Hatano, T; Imagawa, K; Ohishi, Y; Onishi, T; Suzuki, H; Tomita, M, 1998
)
0.48
"We conclude that procainamide has a consistent dose-response relationship with respect to refractoriness and conduction in patients with malignant arrhythmias."( Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia.
Britchkow, D; Kowey, PR; Marinchak, RA; Rials, SJ, 2000
)
0.89
" The approach of the monitored process to the target value followed exponential kinetics and an analytical expression for dependence the variance with time and various dosing parameters was derived."( Pharmacokinetic variability and therapeutic drug monitoring actions at steady state.
Ramanathan, M, 2000
)
0.31
"From a dosing standpoint, large variances in drug concentrations are undesirable because some patients will be overdosed or underdosed."( Pharmacokinetic variability and therapeutic drug monitoring actions at steady state.
Ramanathan, M, 2000
)
0.31
" Log dose-response curves were plotted for quinidine, papaverine, procaine, dibenamine and procaine amide."( A comparison of tests for antifibrillatory action.
SZEKERES, L; WILLIAMS, EM, 1961
)
0.24
" Dose-response curves showed that a concentration of 333 nM TSA was optimal in inducing AChE expression."( Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure.
Compton, JR; Curtin, BF; Doctor, BP; Gordon, RK; Nambiar, MP; Tetz, LM, 2005
)
0.33
" When dosed appropriately in the clinical setting, one bolus of IV procainamide was safe for the treatment of postoperative ventricular arrhythmias."( Comparison of acute hemodynamic effects of lidocaine and procainamide for postoperative ventricular arrhythmias in dogs.
Chandler, JC; Monnet, E; Staatz, AJ,
)
0.61
"To evaluate dosing and pharmacokinetic parameters of intravenous continuous-infusion procainamide in neonates, and to identify dosage regimens and factors leading to therapeutic procainamide levels and minimal adverse events."( Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
Cannon, BC; Friedman, RA; Kertesz, NJ; Moffett, BS, 2006
)
0.84
" The dosage regimen for intravenous procainamide required to achieve therapeutic levels in neonates is similar to that of older infants and children."( Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
Cannon, BC; Friedman, RA; Kertesz, NJ; Moffett, BS, 2006
)
0.89
" We report 4 cases in which procainamide was administered at a dosage of 17 mg/kg in 1 minute."( [Efficacy of procainamide in the treatment of refractory ventricular fibrillation: report of 4 cases and a review of the literature].
Contreras, ZE; Ximena, ZS, 2009
)
1.02
" Therapy with these agents is often complicated because of the presence of significant associated adverse effects, clinician unfamiliarity, variable dosing strategies, and the potential for drug-drug interactions."( Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide.
Mohrien, KM; Oliphant, CS; Samarin, MJ,
)
0.33
"Procainamide is a useful agent for management of ventricular arrhythmia, however its disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown."( Procainamide pharmacokinetics during extracorporeal membrane oxygenation.
Rosenbaum, AN; Vollmer, NJ; Wieruszewski, PM; Wittwer, ED, 2023
)
3.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Procainamide (Antiarrhythmic) Action Pathway478

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.11880.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency21.31380.000221.22318,912.5098AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.55480.000229.305416,493.5996AID743080; AID743091
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency2.37780.133725.412989.1251AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency0.30130.425612.059128.1838AID504536
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency6.30960.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency0.01000.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Mus musculus (house mouse)IC50 (µMol)3.90000.28001.32753.9000AID678794
Solute carrier family 22 member 2Homo sapiens (human)Ki50.00000.10001.52203.4000AID681171
Solute carrier family 22 member 1 Homo sapiens (human)Ki73.90000.55004.26507.4600AID681146
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)389.50000.00032.63119.0000AID1207763
Sterol O-acyltransferase 1Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00580.66266.0000AID31807
Solute carrier family 22 member 2Mus musculus (house mouse)IC50 (µMol)312.00002.80004.76678.0000AID678785
Solute carrier family 22 member 3Homo sapiens (human)Ki738.00000.12000.12000.1200AID681584
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)1.00000.00000.933210.0000AID31167; AID31807
AcetylcholinesteraseHomo sapiens (human)Ki1.00000.00001.27869.7300AID31614
Acetylcholinesterase Bos taurus (cattle)IC50 (µMol)0.50000.00000.61068.7000AID30687
DNA (cytosine-5)-methyltransferase 1Homo sapiens (human)IC50 (µMol)500.00000.01861.64886.0000AID1199269
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)1.00000.02501.79758.0000AID31807
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)389.50000.00032.59559.0000AID1207763
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)138.03800.00091.901410.0000AID243151; AID576612
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)389.50000.00032.63119.0000AID1207763
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)389.50000.00032.25459.6000AID1207763
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)8.90000.18003.68578.8000AID678995; AID678996; AID679317
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki30.00000.13002.37856.9000AID681157; AID681375
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)229.25001.00004.446710.0000AID678968; AID678969; AID679293; AID681158
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki36.00000.39002.32959.4000AID681368
DNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)IC50 (µMol)300.00000.50003.966710.0000AID1199272
DNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)IC50 (µMol)300.00000.50003.733310.0000AID1199272
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Activity14.50000.71005.30179.7000AID681117
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (204)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-templated transcriptionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
epigenetic programming of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to amino acid stimulusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
chromosomal DNA methylation maintenance following DNA replicationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to bisphenol ADNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic processDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switchingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
placenta developmentDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
male meiosis IDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
spermatogenesisDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
methylationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
epigenetic programing of female pronucleusDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
negative regulation of gene expression, epigeneticDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
stem cell differentiationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
chorionic trophoblast cell differentiationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
genomic imprintingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
retrotransposon silencing by heterochromatin formationDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
autosome genomic imprintingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
spermatogenesisDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to xenobiotic stimulusDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to toxic substanceDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to ionizing radiationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to lead ionDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
neuron differentiationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
regulatory ncRNA-mediated heterochromatin formationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
methylationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to estradiolDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to vitamin ADNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
response to cocaineDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
S-adenosylmethionine metabolic processDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cellular response to amino acid stimulusDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cellular response to ethanolDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cellular response to hypoxiaDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
hepatocyte apoptotic processDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
autosome genomic imprintingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
positive regulation of cellular response to hypoxiaDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cellular response to bisphenol ADNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
negative regulation of DNA-templated transcriptionDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (94)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesterase Bos taurus (cattle)
protein bindingAcetylcholinesterase Bos taurus (cattle)
DNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
RNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
protein bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
zinc ion bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
promoter-specific chromatin bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
enzyme activator activityDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
enzyme bindingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
metal ion bindingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
DNA (cytosine-5-)-methyltransferase activity, acting on CpG substratesDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
DNA bindingDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
DNA bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
chromatin bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
transcription corepressor activityDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
DNA (cytosine-5-)-methyltransferase activityDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
protein bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
identical protein bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
unmethylated CpG bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
metal ion bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
lncRNA bindingDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
protein-cysteine methyltransferase activityDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (61)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesterase Bos taurus (cattle)
side of membraneAcetylcholinesterase Bos taurus (cattle)
female germ cell nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleoplasmDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
replication forkDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
pericentric heterochromatinDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ESC/E(Z) complexDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
condensed nuclear chromosomeDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
cytosolDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
catalytic complexDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
heterochromatinDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 3-likeHomo sapiens (human)
chromosome, centromeric regionDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
XY bodyDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
nucleoplasmDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cytoplasmDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
nuclear matrixDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
catalytic complexDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
euchromatinDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
heterochromatinDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
cytoplasmDNA (cytosine-5)-methyltransferase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (291)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID681158TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID57675Amplitude when no compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID678995TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID678806TP_TRANSPORTER: inhibition of TEA uptake in Octn1-HRPE cells2000Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID679203TP_TRANSPORTER: inhibition of TEA uptake (TEA: 500 uM, Procainamide: 5000 uM) in OCT1A expressing Xenopus laevis oocytes1997The Journal of biological chemistry, Jun-27, Volume: 272, Issue:26
Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A).
AID678785TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681368TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1133895Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in PR interval at 40 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 0 ms)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1133880Antiarrhythmic activity in anesthetized acute myocardial infarction dog model assessed as normal ECG complexes at 20 mg/kg, iv administered 10 mins prior to infarction measured during 1-hr postinfarction period (Rvb = 19%)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID22812The maximum percent change from control in the rate of rise of phase 0 of the action potential at 100 uM concentration on Canine Purkinje fibers.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID187370Plasma concentration in rat 5 minutes after administration at a dose of 25 mg/kg1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID678968TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID60459Effect on conversion dose required for arrhythmias in pentobarbital anesthetized dogs1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID61727Resting potential when no compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1146770Competitive inhibition of Escherichia coli B H2-pteroate synthetase assessed as decrease in H2-pteroate formation using [7-14C]-PABA as substrate treated with enzyme for 10 mins prior to substrate challenge for 40 mins by radioassay method1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
P-Aminobenzoic acid derivatives as inhibitors of the cell-free H2-pteroate synthesizing system of Escherichia coli.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID275605Negative inotropic activity assessed as decrease in developed tension in isolated guinea pig left atrium at 0.5 uM relative to control2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel quinolizidinyl derivatives as antiarrhythmic agents.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1133903Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in QT duration at 20 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 2 ms)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID57674Amplitude at 3 x 10e-4 M concentration in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID30697Binding affinity against Acetylcholinesterase of purified calf forebrain (CFB)1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID56829Action potential duration when no compound was administered in Canine Purkinje fibers measured at 70% repolarization1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1149685Antiarrhythmic activity in po dosed Swiss-Webster mouse assessed as protection against chloroform-induced ventricular fibrillation administered in 4% acacia1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides.
AID682012TP_TRANSPORTER: inhibition of TEA uptake (TEA: 140 uM, Procainamide: 10000 uM) in Xenopus laevis oocytes1999Hepatology (Baltimore, Md.), May, Volume: 29, Issue:5
Cloning and functional expression of a mouse liver organic cation transporter.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID491165Positive chronotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate at 100 uM relative to control2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID31807Inhibition of Acetylcholinesterase activity from octopus brain1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID60089Sodium channel inactivating potency at 3*10e-4 M1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID681375TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID1199272Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Targeting DNA methylation with small molecules: what's next?
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID60186Percent change of effective refractory period at 3 x 10e-4 M, in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID30687Inhibition of Acetylcholinesterase activity of calf forebrain1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1217709Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID680396TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Procainamide: 1000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID61726Resting potential at 3 x 10e-4 M in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID678969TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID681952TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Procainamide: 5000 uM) in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID60090Sodium channel inactivating potency in the absence of compound (control)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID588991Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MATE12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID680533TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Procainamide: 500 uM) in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678794TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID655929Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia at 5 x 10'-5 M after 60 mins relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID56093Percent change from control in conduction time (CT) at 10 uM concentration tested on Canine ventricular muscle fibre; value ranges from -12.0-2.01989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID167266Tested in vitro for antiarrhythmic activity in isolated rabbit atria1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiarrhythmic activity of new 3-[2-(omega-aminoalkoxy)phenoxy]-4-phenyl-3-buten-2-ones and related compounds.
AID491158Antiarrhythmic activity in sinusoidal alternating current-induced guinea pig left atrium assessed as increase in current strength at which extra beats occur at 50 uM measured every 30 mins2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID491137Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 100 uM2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation.
AID63282Maximal upstroke velocity when 3*10e-4 M compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1133904Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in QT duration at 40 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 2 ms)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID545725Antiarrhythmic activity in aconitine-intoxicated iv dosed Ivanovas rat assessed as inhibition of ventricular dysfunction2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide.
AID187368Plasma concentration in rat 30 minutes after administration at a dose of 25 mg/kg1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1217706Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217712Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681695TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Procainamide: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1207763Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1133919Hypotensive activity in iv dosed anesthetized dog at higher doses1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID56828Action potential duration at 3 x 10e-4 M measured at 70% repolarization1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID681146TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID75914Concentration which gives a 20% decrease in contractile force on papillary muscle of guinea pig, activity was expressed as EC-20.; NR is not reached.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID187367Plasma concentration in rat 2 hr after administration at a dose of 25 mg/kg1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1776039Stability of compound in human plasma assessed as half life at 20 uM incubated for 3 hrs by LC-MS (SIM) assay2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID22811The maximum change from control in the rate of rise of phase 0 of the action potential at 10 uM concentration on Canine Purkinje fibers.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID679293TP_TRANSPORTER: inhibition pramipexole uptake in rOCT2-injected oocytes2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.
AID588966Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID76706Parasympatholytic activity was assessed from the ability to inhibit electrically stimulated contraction of isolated guinea pig ileum at 4 mg/L of base1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.
AID187369Plasma concentration in rat 4 hr after administration at a dose of 25 mg/kg1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1217707Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID678996TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID61725Percent change of resting potential at 3 x 10e-4 M in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID60182Effective refractory period when no compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID275611Positive chronotropic activity in isolated guinea pig right atrium relative to control2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel quinolizidinyl derivatives as antiarrhythmic agents.
AID1133915Reduction in heart rate in anesthetized acute myocardial infarction dog model at 20 mg/kg, iv administered 10 mins prior to infarction (Rvb = 6 bpm)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID134757The compound was tested for acute toxicity when given intraperitoneally in mouse1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiarrhythmic activity of new 3-[2-(omega-aminoalkoxy)phenoxy]-4-phenyl-3-buten-2-ones and related compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID56999Percent change of action potential duration at 3 x 10e-4 M, measured at 95% repolarization in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID681974TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Procainamide: 1000 uM) in OCT2-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID56858Maximum percent change in repolarization at 100 uM concentration on Canine Purkinje fibers.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID56846Action potential duration at 3 x 10e-4 M measured at 95% repolarization in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID56830Percent change of action potential duration at 3 x 10e-4 M, measured at 70% repolarization1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID491148Negative inotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease in developed tension at 0.5 uM relative to control2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation.
AID682272TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM Procainamide: 5000 uM) in OCTN2-expressing HeLa cells1998Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID178118Antiarrhythmic activity ( protection against CaCl2 induced ventricular fibrillation ) in anesthetized rat administered intravenously1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiarrhythmic activity of new 3-[2-(omega-aminoalkoxy)phenoxy]-4-phenyl-3-buten-2-ones and related compounds.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1146772Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
P-Aminobenzoic acid derivatives as inhibitors of the cell-free H2-pteroate synthesizing system of Escherichia coli.
AID1133881Antiarrhythmic activity in anesthetized acute myocardial infarction dog model assessed as normal ECG complexes at 40 mg/kg, iv administered 10 mins prior to infarction measured during 1-hr postinfarction period (Rvb = 19%)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID56985Percent change in repolarization at 10 Purkinje fibers.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID56849Action potential duration when no compound was administered in Canine Purkinje fibers measured at 95% repolarization1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID31933Binding affinity against Acetylcholinesterase of purified Octopus brain (OB)1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID681584TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID56860Maximum percent change in repolarization at 10 uM concentration on Canine Purkinje fibers.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID56083Maximum percent change in conduction time (CT) at 100 uM concentration tested on Canine ventricular muscle fibre1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID275596Activity against alternating current-induced arrhythmia in guinea pig left atrium at 50 uM2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel quinolizidinyl derivatives as antiarrhythmic agents.
AID275639Negative inotropic activity assessed as decrease in developed tension in isolated guinea pig left atrium2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel quinolizidinyl derivatives as antiarrhythmic agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID58609Evaluated for ouabain-induced arrhythmia in anesthetized adult male mongrel dogs. Administered intravenously.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.
AID275614Inhibition of calcium-induced contraction of potassium ion depolarized guinea pig aortic strips at 100 uM2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel quinolizidinyl derivatives as antiarrhythmic agents.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID491141Negative inotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease in developed tension2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation.
AID682297TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Procainamide: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID60838Percent change from control in the functional refractory period (FRP) at 10 uM concentration on Canine ventricular muscle fibre; value ranges from 2-171989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID681973TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Procainamide: 1000 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID63283Maximal upstroke velocity when no compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1217705Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1199269Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Targeting DNA methylation with small molecules: what's next?
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681171TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID22801Percent change from control in the rate of rise of phase 0 of the action potential at 10 uM concentration on Canine Purkinje fibers; value ranges from 8.0-4.01989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID60427Effect on ouabain-induced arrhythmias in pentobarbital anesthetized dogs1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID60181Effective refractory period at 3 x 10e-4 M in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID63425Percent change in maximal upstroke velocity when 3*10e-4 M compound was administered in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID1133894Effect on cardiac conduction in anesthetized acute myocardial infarction dog model assessed as increase in PR interval at 20 mg/kg, iv administered 10 mins prior to infarction measured after 10 mins (Rvb = 0 ms)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1217708Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID184788The compound was tested for acute toxicity when given intravenously in rat1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiarrhythmic activity of new 3-[2-(omega-aminoalkoxy)phenoxy]-4-phenyl-3-buten-2-ones and related compounds.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID56087Maximum percent change in conduction time (CT) at 1 uM concentration tested on Canine ventricular muscle fibre1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID60088Sodium channel inactivating potency at 3*10e-4 M1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1133918Myocardial depressant activity in iv dosed anesthetized dog at higher doses1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1133914Reduction in heart rate in anesthetized acute myocardial infarction dog model at 40 mg/kg, iv administered 10 mins prior to infarction (Rvb = 6 bpm)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
2-, 3-, and 4-(alpha, alpha, beta, beta-tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents.
AID60826Maximum percent change in functional refractory period (FRP) at 100 uM on Canine ventricular muscle fibre; value ranges from 7-261989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Heterocyclic analogues of benzamide antiarrhythmic agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID57676Percent change of amplitude at 3 x 10e-4 M concentration in Canine Purkinje fibers1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID31167Inhibition of Acetylcholinesterase from human red blood cells1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID31614Binding affinity against Acetylcholinesterase of human RBC1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
AID679317TP_TRANSPORTER: inhibition pramipexole uptake in rOCT1-injected oocytes2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1799782Inhibitor Screening Assay from Article 10.1074/jbc.M109.039511: \\Inhibition of AcpA phosphatase activity with ascorbate attenuates Francisella tularensis intramacrophage survival.\\2010The Journal of biological chemistry, Feb-19, Volume: 285, Issue:8
Inhibition of AcpA phosphatase activity with ascorbate attenuates Francisella tularensis intramacrophage survival.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,302)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902500 (75.71)18.7374
1990's464 (14.05)18.2507
2000's188 (5.69)29.6817
2010's116 (3.51)24.3611
2020's34 (1.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.83 (24.57)
Research Supply Index8.24 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index134.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials174 (4.82%)5.53%
Reviews314 (8.69%)6.00%
Case Studies387 (10.71%)4.05%
Observational3 (0.08%)0.25%
Other2,734 (75.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias [NCT04234906]Phase 4870 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial [NCT02114528]Phase 440 participants (Anticipated)Interventional2014-10-31Terminated(stopped due to Low recruitment. Pilot trial.)
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department [NCT04485195]Phase 4340 participants (Anticipated)Interventional2021-06-17Recruiting
Management of Supraventricular Tachycardia of Children Admitted to Assiut University Children Hospital(Clinical Audit) [NCT03528616]50 participants (Anticipated)Observational [Patient Registry]2018-05-15Not yet recruiting
ST-segment Elevation With Procainamide as an ECG Endophenotype of AF [NCT01205529]161 participants (Actual)Interventional2010-11-30Completed
Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias [NCT00702117]Phase 4123 participants (Actual)Interventional2008-06-30Completed
Acute Mechanical Response to Anti-arrhythmic Drug Therapy [NCT02575534]0 participants (Actual)Interventional2015-10-31Withdrawn(stopped due to No enrollment in study.)
[NCT00000556]Phase 30 participants Interventional1995-03-31Completed
A Randomized Crossover Trial to Evaluate Electrical Versus Chemical Cardioversion in Patients With Acute Atrial Fibrillation [NCT01994070]Phase 386 participants (Actual)Interventional2013-11-30Completed
[NCT00000464]Phase 30 participants Interventional1987-04-30Completed
[NCT00000518]Phase 30 participants Interventional1985-07-31Completed
Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study [NCT00383799]Phase 4302 participants (Actual)Interventional2005-09-30Terminated(stopped due to Steering Committee decision after inclusion of 74 patients after 6 years and very slow inclusion rate)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01205529 (1) [back to overview]ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous Procainamide

ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous Procainamide

Number of participants who demonstrated ST-segment elevation >1.5mm in the right precordial leads (V1-V3) either at baseline or after sodium channel block with intravenous procainamide infusion. (NCT01205529)
Timeframe: During (5, 10, 15, 20, 25, 30 minutes after initiating) or up to 15 minutes after completion of intravenous procainamide infusion

InterventionParticipants (Count of Participants)
Atrial Fibrillation With ST Changes on Electrocardiogram4

[back to top]